BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications to date. Injectable collagenase is marketed as XIAFLEX® in the U.S. for the treatment of Dupuytren's contracture and Peyronie's disease by BioSpecifics' partner, Endo International plc (Endo). XIAFLEX® is also commercialized in Japan, Europe, Canada and Australia for Dupuytren’s contracture and for Peyronie's disease in Europe and Australia.

Endo is partnered with Paladin Labs, Sobi, Actelion and Asahi Kasei for Dupuytren's contracture and/or Peyronie's disease outside of the U.S.

The XIAFLEX research and development pipeline includes several additional promising indications. Endo is currently managing development for cellulite, adhesive capsulitis, human and canine lipomas, lateral hip fat and plantar fibromatosis. Endo expects to initiate Phase 3 clinical trials of XIAFLEX for the treatment of cellulite in the coming months. BioSpecifics is managing the development of XIAFLEX for uterine fibroids. A Phase 1 clinical trial is ongoing with results expected in 2018.